{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T18:48:37Z","timestamp":1784918917806,"version":"3.55.0"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,10,12]],"date-time":"2024-10-12T00:00:00Z","timestamp":1728691200000},"content-version":"vor","delay-in-days":997,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Flagellate dermatitis (FD) is a rare skin rash, which may occur following the administration of antineoplastic agents. It has been reported following the administration of bleomycin, docetaxel, trastuzumab, cisplatin, bendamustine and doxorubicin. We provide a summary of the epidemiology, aetiology, pathophysiology, and distribution of chemotherapy-induced FD.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>PubMed was searched using ((flagellat*) AND (Dermat*)) OR ((Flagellat*) AND (Erythema)). The search yielded 206 publications, out of which 54 individual case reports were identified which fulfilled our inclusion criteria. Statistical analysis was performed where appropriate.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Female patients were slightly more likely to develop FD compared to males. In the majority of cases FD appeared on the upper and lower limbs and pruritus was an accompanying feature in 51% of cases. Most cases developed after the first cycle of chemotherapy and females were statistically more likely to present within the first 72 hr (p &amp;lt;0.05). Skin biopsies were taken in 41% of cases and this was not statistically associated with the patient\u2019s gender, (p = 0.651), presentation within 72 hr (p = 0.076) or cancer diagnosis. Chemotherapy was stopped in 62% of patients and was associated with female gender (p = 0.0098). Most patients who received treatment were managed with topical steroids. Time for rash resolution ranged from a few weeks to four months following the discontinuation of the causative drug.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>FD is a rare adverse skin effect of chemotherapeutic treatment, most commonly presenting on the upper and lower limbs of patients following their first cycle of chemotherapy. Early presentation is more common in females leading to increased likelihood of stopping chemotherapy. Biopsy findings poorly correlate with disease severity. Continuation of chemotherapy treatment in combination with topical steroids may not adversely affect rash resolution.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1002\/ski2.92","type":"journal-article","created":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T14:19:11Z","timestamp":1642601951000},"source":"Crossref","is-referenced-by-count":7,"title":["A Closer Look at Chemotherapy-Induced Flagellate Dermatitis"],"prefix":"10.1093","volume":"2","author":[{"given":"A.","family":"Constantinou","sequence":"first","affiliation":[{"name":"School of Clinical Medicine, University of Cambridge , Cambridge ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6253-3625","authenticated-orcid":false,"given":"D.","family":"Kotecha","sequence":"additional","affiliation":[{"name":"School of Clinical Medicine, University of Cambridge , Cambridge ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Laouris","sequence":"additional","affiliation":[{"name":"School of Clinical Medicine, University of Cambridge , Cambridge ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"de Paula","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Cambridge , Cambridge ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,1,19]]},"reference":[{"issue":"1","key":"2025010818054157000_ski292-bib-0001","doi-asserted-by":"crossref","first-page":"68","DOI":"10.2165\/11537080-000000000-00000","article-title":"Flagellate dermatitis as a bleomycin-specific adverse effect of cytostatic therapy: a clinical-histopathologic correlation","volume":"12","author":"Ziemer","year":"2011","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"2025010818054157000_ski292-bib-0002","first-page":"293","article-title":"[Cutaneous pigmentation caused by bleomycin]","volume":"77","author":"Moulin","year":"1970","journal-title":"Bull Soc Fr Dermatol Syphiligr"},{"issue":"7","key":"2025010818054157000_ski292-bib-0003","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1200\/JCO.2006.09.7691","article-title":"Bleomycin-induced flagellate erythema","volume":"25","author":"Chen","year":"2007","journal-title":"J Clin Oncol"},{"issue":"5","key":"2025010818054157000_ski292-bib-0004","doi-asserted-by":"crossref","first-page":"e257","DOI":"10.1111\/pde.13234","article-title":"Flagellate dermatitis in a child most likely secondary to doxorubicin","volume":"34","author":"Lim","year":"2017","journal-title":"Pediatr Dermatol"},{"issue":"5","key":"2025010818054157000_ski292-bib-0005","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1177\/1203475416644831","article-title":"Flagellate pattern of toxic erythema of chemotherapy due to doxorubicin: a case report","volume":"20","author":"Vadeboncoeur","year":"2016","journal-title":"J Cutan Med Surg"},{"issue":"4","key":"2025010818054157000_ski292-bib-0006","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s13555-015-0085-2","article-title":"Trastuzumab-associated flagellate erythema: report in a woman with metastatic breast cancer and review of antineoplastic therapy-induced flagellate dermatoses","volume":"5","author":"Cohen","year":"2015","journal-title":"Dermatol Ther"},{"issue":"3","key":"2025010818054157000_ski292-bib-0007","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/j.1365-2230.2007.02633.x","article-title":"Flagellate erythema induced by docetaxel","volume":"33","author":"Tallon","year":"2008","journal-title":"Clin Exp Dermatol"},{"issue":"5","key":"2025010818054157000_ski292-bib-0008","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/ced.12830","article-title":"Flagellate erythema induced by cisplatin","volume":"41","author":"Yamamoto","year":"2016","journal-title":"Clin Exp Dermatol"},{"issue":"11","key":"2025010818054157000_ski292-bib-0009","doi-asserted-by":"crossref","first-page":"12","DOI":"10.5070\/D36QJ3649F","article-title":"Bendamustine-induced \u201cflagellate dermatitis\u201d","volume":"18","author":"Mahmoud","year":"2012","journal-title":"Dermatol Online J"},{"key":"2025010818054157000_ski292-bib-0010","doi-asserted-by":"crossref","first-page":"149","DOI":"10.4103\/0378-6323.129397","article-title":"Flagellate dermatoses","volume":"80","author":"Bhushan","year":"2014","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"3","key":"2025010818054157000_ski292-bib-0011","doi-asserted-by":"crossref","first-page":"213","DOI":"10.4997\/JRCPE.2010.306","article-title":"Toxicities associated with bleomycin","volume":"40","author":"Fyfe","year":"2010","journal-title":"J R Coll Physicians Edinb"},{"issue":"5","key":"2025010818054157000_ski292-bib-0012","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/j.1365-2133.1994.tb04986.x","article-title":"Bleomycin-induced flagellate dermatitis: a clinical and histopathological review","volume":"131","author":"Mowad","year":"1994","journal-title":"Br J Dermatol"},{"issue":"6","key":"2025010818054157000_ski292-bib-0013","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1097\/00000372-199012000-00011","article-title":"Flagellate dermatitis after bleomycin. A histological and immunohistochemical study","volume":"12","author":"Miori","year":"1990","journal-title":"Am J Dermatopathol"},{"issue":"2","key":"2025010818054157000_ski292-bib-0014","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/00003246-199302000-00010","article-title":"Association of hypomagnesemia and mortality in acutely ill medical patients","volume":"21","author":"Rubeiz","year":"1993","journal-title":"Crit Care Med"},{"issue":"3","key":"2025010818054157000_ski292-bib-0015","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/j.1365-2230.1991.tb00352.x","article-title":"Bleomycin-induced flagellate erythema","volume":"16","author":"Duhra","year":"1991","journal-title":"Clin Exp Dermatol"},{"issue":"4","key":"2025010818054157000_ski292-bib-0016","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1001\/archderm.1973.01620190029007","article-title":"Cutaneous toxicity of bleomycin therapy","volume":"107","author":"Cohen","year":"1973","journal-title":"Arch Dermatol"},{"issue":"12","key":"2025010818054157000_ski292-bib-0017","doi-asserted-by":"crossref","DOI":"10.5070\/D31912020716","article-title":"Flagellate erythema","volume":"19","author":"Eungdamrong","year":"2013","journal-title":"Dermatol Online J"},{"issue":"4","key":"2025010818054157000_ski292-bib-0018","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s004030050400","article-title":"Immunohistochemical localization of the neutral cysteine protease bleomycin hydrolase in human skin","volume":"291","author":"Takeda","year":"1999","journal-title":"Arch Dermatol Res"},{"issue":"1","key":"2025010818054157000_ski292-bib-0019","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1684\/ejd.2010.1213","article-title":"Flagellate pigmentation: a unique adverse effect of bleomycin therapy","volume":"21","author":"Al-Khenaizan","year":"2011","journal-title":"Eur J Dermatol"},{"issue":"1","key":"2025010818054157000_ski292-bib-0020","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1046\/j.1365-2230.2003.01114.x","article-title":"Case 2. Bleomycin-induced flagellate dermatosis","volume":"28","author":"Nayak","year":"2003","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"2025010818054157000_ski292-bib-0021","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/DAD.0000000000001271","article-title":"Histological features of flagellate erythema","volume":"41","author":"Ching","year":"2019","journal-title":"Am J Dermatopathol"},{"key":"2025010818054157000_ski292-bib-0022","article-title":"Mortality due to cancer treatment delay: systematic review and meta-analysis","volume":"371","author":"Hanna","year":"2020","journal-title":"BMJ"}],"container-title":["Skin Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ski2.92","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ski2.92","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/skinhd\/article-pdf\/2\/1\/ski2.92\/59726672\/skinhd_2_1_e92.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/skinhd\/article-pdf\/2\/1\/ski2.92\/59726672\/skinhd_2_1_e92.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T18:05:53Z","timestamp":1736359553000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/skinhd\/article\/doi\/10.1002\/ski2.92\/7750109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,19]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,3,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ski2.92","relation":{},"ISSN":["2690-442X"],"issn-type":[{"value":"2690-442X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,3]]},"published":{"date-parts":[[2022,1,19]]},"article-number":"ski2.92"}}